Drug Discovery World
AUGUST 8, 2023
Ginkgo Bioworks and Merck have collaborated to improve the production of biologics. “In particular, we will utilise some of our unique capabilities, such as automated protocols to do predictive ultra high-throughput multiplexed screening, product characterisation and process optimisation. .”
The Pharma Data
JUNE 7, 2023
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 10, 2021
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D.,
XTalks
APRIL 11, 2024
Moreover, rather than producing antibodies, the cancer cells produce abnormal proteins that can cause complications. The companies have also expanded a contract manufacturing agreement with Novartis that will help produce Carvykti for both commercial and clinical supply at the New Jersey plant through the end of 2029.
Pharmaceutical Technology
APRIL 28, 2023
Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.
The Pharma Data
OCTOBER 27, 2020
During the clinical development stage, Molecular Partners will provide clinical supply. The companies will work together to scale-up manufacturing capacity, in collaboration with Sandoz, the generics and biosimilar Novartis division, to provide worldwide supply. million doses of MP0420, if it is approved in Switzerland.
The Pharma Data
NOVEMBER 22, 2020
MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells. DARPin® therapeutics have been clinically validated through to the registrational stage. Chief Medical Officer of Molecular Partners. About DARPin® therapeutics.
Expert insights. Personalized for you.
52 
Let's personalize your content